{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:50:35Z","timestamp":1789102235336,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.clinbiochem.2020.11.003","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T15:38:13Z","timestamp":1605886693000},"page":"18-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Setting minimum clinical performance specifications for tests based on disease prevalence and minimum acceptable positive and negative predictive values: Practical considerations applied to COVID-19 testing"],"prefix":"10.1016","volume":"88","author":[{"given":"Tze Ping","family":"Loh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2763-5949","authenticated-orcid":false,"given":"Sarah J","family":"Lord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0137-3218","authenticated-orcid":false,"given":"Katy","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Kathryn","family":"Bohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun Yee","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Markus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernan","family":"Fares Taie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khosrow","family":"Adeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9523-9054","authenticated-orcid":false,"given":"Giuseppe","family":"Lippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sverre","family":"Sandberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2020.11.003_b0005","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus from Patients with Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clinbiochem.2020.11.003_b0010","unstructured":"World Health Organization. WHO Director-General\u2019s opening remarks at the media briefing on COVID-19 \u2013 11 March 2020. https:\/\/www.who.int\/dg\/speeches\/detail\/who-directorgeneral-s-opening-remarks-at-the-media-briefing-on-covid-19---11-March-2020. (Accessed: 1 May 2020)."},{"key":"10.1016\/j.clinbiochem.2020.11.003_b0015","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1515\/cclm-2020-0722","article-title":"Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence","volume":"58","author":"Bohn","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2020.11.003_b0020","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3343\/alm.2020.40.6.439","article-title":"COVID-19 Molecular Testing in Korea: Practical Essentials and Answers From Experts Based on Experiences of Emergency Use Authorization Assays","volume":"40","author":"Sung","year":"2020","journal-title":"Ann. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2020.11.003_b0025","unstructured":"Bohn MK, Mancini N, Loh TP, Wang CB, Grimmler M, Gramegna M, et al. IFCC Interim Guidelines on Molecular Testing of SARS-CoV-2 Infection. Clin Chem Lab Med. 2020 Oct 7:\/j\/cclm.ahead-of-print\/cclm-2020-1412\/cclm-2020-1412.xml. [E-pub ahead of print]."},{"key":"10.1016\/j.clinbiochem.2020.11.003_b0030","unstructured":"Bohn MK, Loh TP, Wang CB, Mueller R, Koch D, Sethi S, et al. IFCC Interim Guidelines on Serological Testing of Antibodies against SARS-CoV-2. Clin Chem Lab Med. 2020 Oct 7:\/j\/cclm.ahead-of-print\/cclm-2020-1413\/cclm-2020-1413.xml. [E-pub ahead of print]."},{"key":"10.1016\/j.clinbiochem.2020.11.003_b0035","unstructured":"Public Health England. COVID-19: PHE assessment of laboratory tests and assays. Information, resources and guidance relating to the evaluation of COVID-19 tests. https:\/\/www.gov.uk\/government\/collections\/covid-19-phe-assessment-of-laboratory-tests-and-assays. (Accessed 20 Aug 2020)."},{"key":"10.1016\/j.clinbiochem.2020.11.003_b0040","unstructured":"U.S. Food & Drug Administration. EUA Authorized Serology Test Performance. https:\/\/www.fda.gov\/medical-devices\/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices\/eua-authorized-serology-test-performance. (Accessed 20 Aug 2020)."},{"key":"10.1016\/j.clinbiochem.2020.11.003_b0045","unstructured":"Egner W. Verification and validation methodology and sample sets for evaluation of assays for SARS-CoV-2 (COVID-19). https:\/\/www.rcpath.org\/uploads\/assets\/541a4523-6058-4424-81c119dd2ab0febb\/Verification-validation-of-sample-sets-assays-SARS-CoV-2.pdf. Accessed 20 Aug 2020)."},{"key":"10.1016\/j.clinbiochem.2020.11.003_b0050","unstructured":"Medicine & Healthcare Products Regulatory Agency. Target product profile: antibody tests to help determine if people have immunity to SARS-CoV-2: version 2. https:\/\/www.gov.uk\/government\/publications\/how-tests-and-testing-kits-for-coronavirus-covid-19-work\/target-product-profile-antibody-tests-to-help-determine-if-people-have-recent-infection-to-sars-cov-2-version-2. (Accessed 20 Aug 2020)."},{"key":"10.1016\/j.clinbiochem.2020.11.003_b0055","unstructured":"Theel E, Filkins L, Palavecino E, Mitchell S, Campbell S, Pentella M, et al. Verification procedure for commercial serologic tests with Emergency Use Authorization for detection of antibodies to SARS-CoV-2. https:\/\/asm.org\/ASM\/media\/Protocol-Images\/ASM-Web-protocol-serology-062220-FINAL.pdf?ext=.pdf. (Accessed 20 Aug 2020)."},{"key":"10.1016\/j.clinbiochem.2020.11.003_b0060","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cca.2013.09.018","article-title":"From biomarkers to medical tests: the changing landscape of test evaluation","volume":"427","author":"Horvath","year":"2014","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.clinbiochem.2020.11.003_b0065","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1177\/0004563219842265","article-title":"Setting clinical performance specifications to develop and evaluate biomarkers for clinical use","volume":"56","author":"Lord","year":"2019","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.clinbiochem.2020.11.003_b0070","doi-asserted-by":"crossref","unstructured":"Lalkhen A.G., McCluskey A. Clinical tests: sensitivity and specificity. Continuing Education in Anaesthesia Critical Care & Pain 2008;8:221-3.","DOI":"10.1093\/bjaceaccp\/mkn041"},{"key":"10.1016\/j.clinbiochem.2020.11.003_b0075","article-title":"Testing decisions in the Pandemic: How do we use imperfect tests for COVID-19 (SARS-CoV-2) to make clinical decisions?","author":"Bell","year":"2020","journal-title":"Med. J. Aus."},{"key":"10.1016\/j.clinbiochem.2020.11.003_b0080","unstructured":"Public Health England. COVID-19: laboratory evaluations of serological assays. https:\/\/www.gov.uk\/government\/publications\/covid-19-laboratory-evaluations-of-serological-assays. (Accessed 20 Aug 2020)."},{"key":"10.1016\/j.clinbiochem.2020.11.003_b0085","doi-asserted-by":"crossref","unstructured":"J.J. Deeks, J. Dinnes, Y. Takwoingi, C. Davenport, R. Spijker, S. Taylor-Phillips, et al. Antibody tests for identification of current and past infection with SARS-CoV-2 Cochrane Database, Syst. Rev. 2020, 6, CD013652.","DOI":"10.1002\/14651858.CD013652"},{"issue":"13","key":"10.1016\/j.clinbiochem.2020.11.003_b0090","first-page":"20152793","article-title":"At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR based tests? A systematic review of individual participant data","volume":"07","author":"Mallett","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.clinbiochem.2020.11.003_b0095","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/aje\/kwm188","article-title":"An evaluation of classification rules based on date of symptom onset to identify health-care associated infections","volume":"166","author":"Lessler","year":"2007","journal-title":"Am. J. Epidemiol."},{"issue":"16","key":"10.1016\/j.clinbiochem.2020.11.003_b0100","first-page":"20066787","article-title":"False negative results of initial RT-PCR assays for COVID-19: a systematic review","volume":"04","author":"Arevalo-Rodriguez","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.clinbiochem.2020.11.003_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102916","article-title":"Spatial and temporal dynamics of SARS-CoV-2 in COVID-19 patients: A systematic review and meta-analysis","volume":"58","author":"Weiss","year":"2020","journal-title":"EBioMedicine"}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912020308808?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912020308808?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:56:27Z","timestamp":1757865387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912020308808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":21,"alternative-id":["S0009912020308808"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2020.11.003","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Setting minimum clinical performance specifications for tests based on disease prevalence and minimum acceptable positive and negative predictive values: Practical considerations applied to COVID-19 testing","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2020.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}